ScholarIQanswers from OpenAlex
National Cancer Institute
FunderResearch funding and supported work
National Cancer Institute is a funder indexed in ScholarIQ from OpenAlex.
What is known about National Cancer Institute?
ScholarIQrecord summary
US research institute, part of National Institutes of Health
How many works does National Cancer Institute have?
ScholarIQindexed works
National Cancer Institute has 701,605 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for National Cancer Institute?
ScholarIQopenalex
The OpenAlex for National Cancer Institute is on the source record.
What is the ROR of National Cancer Institute?
ScholarIQror
The ROR for National Cancer Institute is on the source record.
What are the most-cited papers on National Cancer Institute?
ScholarIQmost cited works
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Robert L. Coleman, Gini F. Fleming, Mark F. Brady, Elizabeth M. Swisher, Karina Dahl Steffensen, Michael Friedländer, Aikou Okamoto, Kathleen N. Moore, Noa Ben-Baruch, Theresa L. Werner, Noelle Cloven, Ana Oaknin, Paul DiSilvestro, Mark A. Morgan, Joo‐Hyun Nam, Charles A. Leath, Shibani Nicum, Andrea R. Hagemann, Ramey D. Littell, David Cella, Sally Baron‐Hay, Jesús García-Donás, Mika Mizuno, Katherine M. Bell‐McGuinn, Danielle Sullivan, Bruce Allen Bach, Sudipta Bhattacharya, Christine K. Ratajczak, Peter Ansell, Minh H. Dinh, Carol Aghajanian, Michael A. Bookman
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, John McNamara, Elizabeth Lowe, Mei-Lin Ah-See, Kathleen N. Moore, on behalf of the SOLO1 Investigators
<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
Nicolas Marcoux, Scott Gettinger, Grainne M. O’Kane, Kathryn C. Arbour, Joel W. Neal, Hatim Husain, Tracey L. Evans, Julie R. Brahmer, Alona Muzikansky, Philip Bonomi, Salvatore Del Prete, Anna Wurtz, Anna F. Farago, Dora Dias‐Santagata, Mari Mino–Kenudson, Karen L. Reckamp, Helena A. Yu, Heather A. Wakelee, Frances A. Shepherd, Zofia Piotrowska, Lecia V. Sequist
Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial
Frank A. Vicini, Reena S. Cecchini, Julia White, Douglas W. Arthur, Thomas B. Julian, Rachel Rabinovitch, Robert R. Kuske, Patricia A. Ganz, David S. Parda, Michael F. Scheier, Kathryn Winter, Soonmyung Paik, Henry M. Kuerer, Laura A. Vallow, Lori J. Pierce, Eleftherios P. Mamounas, Beryl McCormick, Joseph P. Costantino, Harry D. Bear, Isabelle Germain, G.S. Gustafson, Linda Grossheim, Ivy A. Petersen, Richard Hudes, Walter J. Curran, John Bryant, Norman Wolmark
Heterogeneity Underlies the Emergence of <i>EGFR</i> T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Zofia Piotrowska, Matthew J. Niederst, Chris Karlovich, Heather A. Wakelee, Joel W. Neal, Mari Mino–Kenudson, Linnea Fulton, Aaron N. Hata, Elizabeth L. Lockerman, Anuj Kalsy, Subba R. Digumarthy, Alona Muzikansky, Mitch Raponi, Angel R. Garcia, Hillary E. Mulvey, Melissa Parks, Richard H. DiCecca, Dora Dias‐Santagata, A. John Iafrate, Alice T. Shaw, Andrew R. Allen, Jeffrey A. Engelman, Lecia V. Sequist